Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
AGPS CRISPR/Cas9 KO Plasmid (m): sc-432759
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AGPS CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the AGPS genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: AGPS Antibody (A-2): sc-374201
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AGPS CRISPR/Cas9 KO Plasmid (m) | sc-432759 | 20 µg | $397.00 |
Overview
Agps encodes alkylglycerone phosphate synthase (AGPS), a peroxisomal enzyme that catalyzes a key ether-bond–forming step in plasmalogen biosynthesis. By controlling cellular pools of ether phospholipids, AGPS contributes to membrane architecture, lipid raft composition, and redox buffering through plasmalogen-associated antioxidant capacity. AGPS-dependent lipid remodeling influences peroxisome–endoplasmic reticulum metabolic coupling and broader glycerophospholipid homeostasis. Disruption of ether lipid metabolism is implicated in peroxisome-related metabolic phenotypes and neurodevelopmental dysfunction, supporting the use of Agps perturbation to model pathway-level lipid defects in mouse systems.
AGPS CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Agps gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Agps together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Agps open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish AGPS protein expression.
This CRISPR knockout system enables efficient generation of Agps-deficient cell models for investigation of AGPS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Agps exon(s) critical for AGPS function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Agps genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by AGPS CRISPR/Cas9 KO Plasmid (m) and AGPS CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Agps locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by AGPS HDR Plasmid (m) and AGPS HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Agps homology arms to support homology-directed repair at defined Agps target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.